Candida parapsilosis resistance to fluconazole: Molecular mechanisms and in vivo impact in infected Galleria mellonella larvae

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6581-6587

  Souza, Ana Carolina R ^a   Fuchs, Beth Burgwyn ^b   Pinhati, Henrique M S ^c,d   Siqueira, Ricardo A ^a   Hagen, Ferry ^e   Meis, Jacques F ^e,f   Mylonakis, Eleftherios ^b   Colombo, Arnaldo L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF BRASILIA   (Brazil)

^d Hospital Santa Luzia   (Brazil)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; FLUCONAZOLE; MICROSATELLITE DNA; MULTIDRUG RESISTANCE PROTEIN 1; VORICONAZOLE; ANTIFUNGAL AGENT;

AMINO ACID SUBSTITUTION; ANIMAL MODEL; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTHROPOD LARVA; ARTICLE; CANDIDA PARAPSILOSIS; CANDIDIASIS; CDR1 GENE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; ERG11 GENE; EXPERIMENTAL MODEL; FUNGAL GENE; FUNGAL STRAIN; FUNGUS IDENTIFICATION; GALLERIA MELLONELLA; GENE OVEREXPRESSION; GENE SEQUENCE; IN VIVO STUDY; INSECT DISEASE; MDR1 GENE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; CANDIDA; DRUG EFFECTS; LARVA; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOTH; PATHOGENICITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; LARVA; MICROBIAL SENSITIVITY TESTS; MOTHS;

EID: 84942279817     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01177-15     Document Type: Article

References (57)

1. Trofa D, Gacser A, Nosanchuk JD. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 21:606-625. http://dx.doi.org/10.1128/CMR.00013-08.
2. Pammi M, Holland L, Butler G, Gacser A, Bliss JM. 2013. Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis. Pediatr Infect Dis J 32:e206-e216. http://dx.doi.org/10.1097/INF.0b013e3182863a1c.
3. Quindós G. 2014. Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol 31:42-48. http://dx.doi.org/10.1016/j.riam.2013.10.001.
4. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M, Saballs P, Fridkin SK, Morgan J, Rodriguez-Tudela JL, Warnock DW, Pahissa A, Barcelona Candidemia Project Study Group.2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43:1829-1835. http://dx.doi.org/10.1128/JCM.43.4.1829-1835.2005.
5. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. 2006. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21. http://dx.doi.org/10.1186/1471-2334-6-21.
6. Colombo AL, Nucci M, Park BJ, Nouer SA, Arthington-Skaggs B, da Matta DA, Warnock D, Morgan J, Brazilian Network Candidemia Study. 2006. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 44:2816-2823. http://dx.doi.org/10.1128/JCM.00773-06.
7. Bassetti M, Merelli M, Righi E, Diaz-Martin A, Rosello EM, Luzzati R, Parra A, Trecarichi EM, Sanguinetti M, Posteraro B, Garnacho-Montero J, Sartor A, Rello J, Tumbarello M. 2013. Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol 51:4167-4172. http://dx.doi.org/10.1128/JCM.01998-13.
8. Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, Guzman-Blanco M, Santolaya ME, Thompson L, Sifuentes-Osornio J, Echevarria JI, Colombo AL, Latin American Invasive Mycosis Network. 2013. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 8:e59373. http://dx.doi.org/10.1371/journal.pone.0059373.
9. Marcos-Zambrano LJ, Escribano P, Sanchez C, Munoz P, Bouza E, Guinea J. 2014. Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565-4572. http://dx.doi.org/10.1128/AAC.02670-14.
10. Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE. 2014. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One 9:e101510. http://dx.doi.org/10.1371/journal.pone.0101510.
11. Moudgal V, Little T, Boikov D, Vazquez JA. 2005. Multiechinocandinand multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49:767-769. http://dx.doi.org/10.1128/AAC.49.2.767-769.2005.
12. Sarvikivi E, Lyytikainen O, Soll DR, Pujol C, Pfaller MA, Richardson M, Koukila-Kahkola P, Luukkainen P, Saxen H. 2005. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 43:2729-2735. http://dx.doi.org/10.1128/JCM.43.6.2729-2735.2005.
13. Cantón E, Peman J, Quindos G, Eraso E, Miranda-Zapico I, Alvarez M, Merino P, Campos-Herrero I, Marco F, de la Pedrosa EG, Yague G, Guna R, Rubio C, Miranda C, Pazos C, Velasco D, FUNGEMYCA Study Group. 2011. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 55:5590-5596. http://dx.doi.org/10.1128/AAC.00466-11.
14. Cleveland AA, Farley MM, Harrison LH, Stein B, Hollick R, Lockhart SR, Magill SS, Derado G, Park BJ, Chiller TM. 2012. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis 55:1352-1361. http://dx.doi.org/10.1093/cid/cis697.
15. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
16. Pfaller MA, Jones RN, Castanheira M. 2014. Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. Mycoses 57:602-611. http://dx.doi.org/10.1111/myc.12206.
17. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48:503-535. http://dx.doi.org/10.1086/596757.
18. Colombo AL, Guimaraes T, Camargo LF, Richtmann R, Queiroz-Telles F, Salles MJ, Cunha CA, Yasuda MA, Moretti ML, Nucci M. 2013. Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infect Dis 17:283-312. http://dx.doi.org/10.1016/j.bjid.2013.02.001.
19. Georgopapadakou NH, Walsh TJ. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother 40:279-291.
20. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39:2378-2386. http://dx.doi.org/10.1128/AAC.39.11.2378.
21. Albertson GD, Niimi M, Cannon RD, Jenkinson HF. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob Agents Chemother 40:2835-2841.
22. Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, Godoy Martinez PC, Goldman MH, Colombo AL. 2004. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 50:25-32. http://dx.doi.org/10.1016/j.diagmicrobio.2004.04.009.
23. Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. 2014. Mechanisms of antifungal drug resistance. Cold Spring Harb Perspect Med 5:a019752. http://dx.doi.org/10.1101/cshperspect.a019752.
24. Heilmann CJ, Schneider S, Barker KS, Rogers PD, Morschhäuser J. 2010. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob Agents Chemother 54:353-359. http://dx.doi.org/10.1128/AAC.01102-09.
25. Sanglard D, Ischer F, Koymans L, Bille J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 42:241-253. http://dx.doi.org/10.1093/jac/42.2.241.
26. Monk BC, Tomasiak TM, Keniya MV, Huschmann FU, Tyndall JD, O'Connell JD, III, Cannon RD, McDonald JG, Rodriguez A, Finer-Moore JS, Stroud RM. 2014. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci U S A 111:3865-3870. http://dx.doi.org/10.1073/pnas.1324245111.
27. Pinhati HM, Casulari LA, Bizerra FC, Siqueira RA, Castro FF, Colombo AL. 2013. Outbreak of candidemia due to fluconazole resistant Candida parapsilosis strains in a tertiary care hospital in Brazil, abstr K-1707. Abstr 53th Intersci Conf Antimicrob Agents Chemother.
28. Jain P, Khan ZK, Bhattacharya E, Ranade SA. 2001. Variation in random amplified polymorphic DNA (RAPD) profiles specific to fluconazole-resistant and -sensitive strains of Candida albicans. Diagn Microbiol Infect Dis 41:113-119. http://dx.doi.org/10.1016/S0732-8893(01)00292-9.
29. Souza AC, Ferreira RC, Goncalves SS, Quindos G, Eraso E, Bizerra FC, Briones MR, Colombo AL. 2012. Accurate identification of Candida parapsilosis (sensu lato) by use of mitochondrial DNA and real-time PCR. J Clin Microbiol 50:2310-2314. http://dx.doi.org/10.1128/JCM.00303-12.
30. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. CLSI, Wayne, PA.
31. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts. Fourth informational supplement M27-S4. CLSI, Wayne, PA.
32. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol 50:2846-2856. http://dx.doi.org/10.1128/JCM.00937-12.
33. Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrugresistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33:919-926. http://dx.doi.org/10.1007/s10096-013-2027-1.
34. Diab-Elschahawi M, Forstner C, Hagen F, Meis JF, Lassnig AM, Presterl E, Klaassen CH. 2012. Microsatellite genotyping clarified conspicuous accumulation of Candida parapsilosis at a cardiothoracic surgery intensive care unit. J Clin Microbiol 50:3422-3426. http://dx.doi.org/10.1128/JCM.01179-12.
35. Mylonakis E, Moreno R, El Khoury JB, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. 2005. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 73: 3842-3850. http://dx.doi.org/10.1128/IAI.73.7.3842-3850.2005.
36. Fuchs BB, O'Brien E, Khoury JB, Mylonakis E. 2010. Methods for using Galleria mellonella as a model host to study fungal pathogenesis. Virulence 1:475-482. http://dx.doi.org/10.4161/viru.1.6.12985.
37. Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, Baughman W, Stein B, Hollick R, Park BJ, Chiller T. 2012. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011. J Clin Microbiol 50:3435-3442. http://dx.doi.org/10.1128/JCM.01283-12.
38. Morschhäuser J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587:240-248. http://dx.doi.org/10.1016/S0925-4439(02)00087-X.
39. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, Calabrese D, Sanglard D, Patterson TF. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 45:2676-2684. http://dx.doi.org/10.1128/AAC.45.10.2676-2684.2001.
40. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. 2005. Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother 49:4608-4615. http://dx.doi.org/10.1128/AAC.49.11.4608-4615.2005.
41. Morio F, Loge C, Besse B, Hennequin C, Le Pape P. 2010. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 66:373-384. http://dx.doi.org/10.1016/j.diagmicrobio.2009.11.006.
42. Hull CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL. 2012. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrob Agents Chemother 56:4223-4232. http://dx.doi.org/10.1128/AAC.06253-11.
43. Jiang C, Dong D, Yu B, Cai G, Wang X, Ji Y, Peng Y. 2013. Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother 68:778-785. http://dx.doi.org/10.1093/jac/dks481.
44. Forastiero A, Mesa-Arango AC, Alastruey-Izquierdo A, Alcazar-Fuoli L, Bernal-Martinez L, Pelaez T, Lopez JF, Grimalt JO, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E. 2013. Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications. Antimicrob Agents Chemother 57:4769-4781. http://dx.doi.org/10.1128/AAC.00477-13.
45. Couzigou C, Gabriel F, Biteau N, Fitton-Ouhabi V, Noel T, Accoceberry I. 2014. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia. Med Mycol Case Rep 5:12-15. http://dx.doi.org/10.1016/j.mmcr.2014.04.002.
46. Grossman NT, Pham CD, Cleveland AA, Lockhart SR. 2015. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother 59:1030-1037. http://dx.doi.org/10.1128/AAC.04613-14.
47. Barchiesi F, Calabrese D, Sanglard D, Falconi Di Francesco L, Caselli F, Giannini D, Giacometti A, Gavaudan S, Scalise G. 2000. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother 44:1578-1584. http://dx.doi.org/10.1128/AAC.44.6.1578-1584.2000.
48. Perea S, Lopez-Ribot JL, Wickes BL, Kirkpatrick WR, Dib OP, Bachmann SP, Keller SM, Martinez M, Patterson TF. 2002. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46:1695-1703. http://dx.doi.org/10.1128/AAC.46.6.1695-1703.2002.
49. Redding SW, Kirkpatrick WR, Coco BJ, Sadkowski L, Fothergill AW, Rinaldi MG, Eng TY, Patterson TF. 2002. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Microbiol 40:1879-1881. http://dx.doi.org/10.1128/JCM.40.5.1879-1881.2002.
50. Rogers PD, Vermitsky JP, Edlind TD, Hilliard GM. 2006. Proteomic analysis of experimentally induced azole resistance in Candida glabrata. J Antimicrob Chemother 58:434-438. http://dx.doi.org/10.1093/jac/dkl221.
51. Tavakoli M, Zaini F, Kordbacheh M, Safara M, Raoofian R, Heidari M. 2010. Upregulation of the ERG11 gene in Candida krusei by azoles. Daru 18:276-280.
52. Silva AP, Miranda IM, Guida A, Synnott J, Rocha R, Silva R, Amorim A, Pina-Vaz C, Butler G, Rodrigues AG. 2011. Transcriptional profiling of azole-resistant Candida parapsilosis strains. Antimicrob Agents Chemother 55:3546-3556. http://dx.doi.org/10.1128/AAC.01127-10.
53. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC. 1998. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 42:1819-1830.
54. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhäuser J. 2001. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob Agents Chemother 45:3416-3421. http://dx.doi.org/10.1128/AAC.45.12.3416-3421.2001.
55. Moran G, Sullivan D, Morschhäuser J, Coleman D. 2002. The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance. Antimicrob Agents Chemother 46:2829-2841. http://dx.doi.org/10.1128/AAC.46.9.2829-2841.2002.
56. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez T, Bouza E. 2006. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med Mycol 44:575-578. http://dx.doi.org/10.1080/13693780600561544.
57. Souza AC, Fuchs BB, Siqueira RA, Pinhati HM, Mylonakis E, Colombo AL. 2014. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr M-1094.